source
- Genentech pours $750M into new drug‑delivery device plant in Oregon; Bavarian Nordic pushes back Lyme vaccine trialRoche’s Genentech announced a $750 million investment to build a new drug‑delivery device manufacturing facility at its Hillsboro, Oregon campus. The plant is intended to expand the company’s capac…
- Study suggests cancer patients may be receiving higher doses and longer treatment courses than neededRecent analysis highlighted that many cancer patients are being treated with larger drug doses and extended therapy durations than may be medically necessary. The pattern raises concerns about unn…